Law360, New York (December 16, 2013, 6:40 PM ET) -- A New Jersey federal judge on Friday barred Mylan Inc. from manufacturing, importing or selling its own version of Teva Pharmaceutical Industries Ltd.'s brand-name treatment for Parkinson's disease, Azilect, for more than three years, after the generic-drug maker stipulated its proposed generic infringed a Teva patent.

U.S. District Judge Claire C. Cecchi embraced the injunction that Teva had been calling for, after the two pharmaceutical manufacturers disputed what form the court's final judgment should take, with Mylan advocating for an order that would only stop it...

the best solution?
a cure!!!!
for other MAO-B inhibitors there is a sublingual form of selegilene which i imagine is expensive and good old selegilene for alternatives but even it and generic C/L is getting more expensive and fewer companies manufacture these drugs.

and then you have the problem of less effective generics, possibly more so with extended release generics.